Stent sparring resumes
This article was originally published in The Gray Sheet
Executive Summary
Medinol is seeking royalties from past and future sales of Boston Scientific's Liberté and Taxus Liberté paclitaxel-eluting stent based on its assertion that the stent violates several patents. The Israeli firm filed suit with the World Intellectual Property Organization in Geneva on Feb. 21. In Sept. 2005, Boston Scientific agreed to pay its one-time partner $750 mil. to settle a long-running patent infringement suit related to its Express and first-generation Taxus stents (1"The Gray Sheet" Sept. 26, 2005, p. 11). Medinol also is pursuing patent litigation with Guidant...